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It has been reported that gonadotropin‑releasing hormone (GnRH), and its analogue leuprolide acetate (LA), have 
neurotrophic properties; particularly in the regeneration of injured spinal cord in animal models and in the case of a patient 
with spinal cord injury (SCI). The aim of this study was to establish whether treatment with LA improves sensitivity, motor 
activity and independence in patients with chronic SCI. Patients were treated LA once a month for six months. They were 
evaluated at the beginning and at the end of treatment; using a  sensitivity and motor impairment scale, according to 
the American Spinal Injury Association (ASIA), and grade of independence scale; employing the spinal cord independence 
measure (SCIM). Statistical analysis showed a significant improvement in the ASIA sensory score and the SCIM score when 
comparing the initial versus final evaluation after six months of LA administration. Some patients showed an increase in 
frequency of bowel movements. Treatment with LA induces improvements in sensitivity, motor activity and independence 
in patients with chronic SCI. One advantage of this protocol is that it is a non‑invasive method of easy and safe application, 
with few side effects. 
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INTRODUCTION
Spinal cord injury (SCI) temporarily or permanent‑
ly disrupts neuroanatomical circuitry and can result in 
severe deficits such as loss of motor, sensory, and auto‑
nomic functions. Management of the SCI has change in 
recent years, both in acute and chronic lesions. There 
are different small trials performed for the acute and 
chronic SCI in course, among which are the use of 
neurotrophic factors, Nogo neutralizing antibodies, 
N‑methyl‑D‑aspartate receptor modulators and autolo‑
gous mesenchymal stem cells (Varma et al. 2013).
In animal models of SCI, neurotrophic factors play 
an important role for improvement of injury nervous 
system and behavioral effects. In all these models, an 
acute and intra‑lesion administration of the neuro‑
trophic factors is required to show the outcome (Har‑
vey et al. 2015). In recent years, it has been reported 
that gonadotropin‑releasing hormone (GnRH) and its 
analogue, leuprolide acetate (LA), have neurotrophic 
properties. In vitro, GnRH incubation induced chang‑
es in outgrowth, number and length of neurites in 
rat cerebral cortical neurons and spinal cord neurons 
(Quintanar and Salinas 2008, Quintanar et al. 2016a). 
In vivo, administration of GnRH improves locomotor 
activity and bladder function, and increases the ex‑
pression of neurofilaments in spinal cord in rats with 
SCI (Calderón‑Vallejo et al. 2015, Calderón‑Vallejo and 
Quintanar 2012). Likewise, the administration of LA im‑
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proves locomotor activity, gait, micturition reflex and 
spinal cord morphology in rats with SCI (Díaz‑Galindo 
et al. 2015). The use of LA has certain advantages over 
the natural hormone GnRH. The agonist is less suscep‑
tible to proteolysis than GnRH, and has a greater bind‑
ing affinity to receptors than the natural hormone, in‑
creasing its biological activity (Periti et al. 2002). It is 
also able to cross the blood‑spinal cord barrier (Barrera 
et al. 1991).
Regarding the current clinical therapies and ani‑
mal trials mentioned above, most of these treatments 
have an acute approach, which means that the treat‑
ment begins immediately after the injury. For clini‑
cal purposes, the term “chronic” is used to refer the 
period after the initial hospitalization (Ditunno and 
Formal 1994). The chronic SCI has a several system‑
ic complications; these could be a cardiovascular re‑
sponse (orthostatic hypotension, bradycardia), auto‑
nomic dysreflexia (cardiac, bladder, bowel, tempera‑
ture, and sexual dysfunction), pulmonary, hyponatre‑
mia, deep vein thrombosis, pressure ulcers, spastici‑
ty, neuropathic pain, among others (Sweis and Biller 
2017), and most of these complications only have sup‑
port management.
Currently, and parallel to these previous informa‑
tion, LA is used in humans for diverse clinical appli‑
cations related to endocrine pathologies; including 
palliative treatment of prostate cancer, management 
of endometriosis, as a concomitant therapy for uterine 
leiomyomata, and central precocious puberty (Wilson 
et al. 2007). It is well established that the side effects of 
chronic treatment with LA is a decrease in levels of sex 
hormones (Mathias et al. 1998). In a preliminary study, 
independent of the therapeutic effects related to en‑
docrine diseases, we tested the treatment in a patient 
with chronic SCI and after 12 months of application, 
sensitivity and motor functions were partially recov‑
ered (Quintanar et al. 2016b). 
Considering that LA acts as a drug with neurotroph‑
ic proprieties, already used in humans for other patho‑
logical conditions, able to cross the blood‑spinal cord 
barrier after an intramuscular administration, and 
with few and well described side effects, the aim of this 
work was to establish whether treatment with LA im‑
proves sensitivity, motor activity and independence in 
patients with chronic SCI.
METHODS
Study design and site
This is a prospective, non‑masked, pilot type phase 
II clinical trial. The study was carried out at the Clin‑
ic of Integral Rehabilitation, Universidad Autónoma de 
Aguascalientes, México.
Inclusion and exclusion criteria
Inclusion criteria were: aged between 18 to 60 years, 
diagnosis of chronic SCI (patient who had SCI longer 
than 5 months) confirmed by clinical evaluation with 
American Spinal Injury Association (ASIA) impairment 
scale A or B, computed tomography or magnetic reso‑
nance imaging scan of the lesion, and establishment of 
damage with no evidence of neurological improvement 
prior the treatment. Patients were excluded from the 
study if they had any of the following: non‑traumat‑
ic cause of the lesion (vascular, tumors, surgery, and 
special cases), impairment health status or terminal 
disease, and currently participating in another clinical 
research protocol. 
Study protocol
Fourteen patients were included in this study cho‑
sen according to inclusion criteria described above. All 
the participants gave their informed consent in writ‑
ing and the procedure was carried out in agreement 
with the local Bioethics Committee of the Universi‑
dad Autónoma de Aguascalientes. The patients have 
a clinical evaluation which include: clinical history, 
ASIA impairment scale (Ditunno et al. 1994), and grade 
of independence using the spinal cord independence 
measure (SCIM) (Catz et al. 1997). Following the initial 
evaluation, intramuscular administration of 3.75 mg of 
LA (Lucrin Depot 3.75 mg, Abbott Laboratories, Chica‑
go, IL) commenced. The drug was applied monthly for 
six months. At the end of six month of treatment, an‑
other evaluation was performed including ASIA impair‑
ment scale, grade of independence with SCIM and any 
other finding observation. During the treatment, pa‑
tients continued with their usual activities, which in‑
cluded physical rehabilitation (all patients for at least 
3 hours/week).
Statistical method
The goal of the study was to test the null hypoth‑
esis that the mean difference between basal and fol‑
low‑up (at 6‑month treatment) of ASIA sensory, ASIA 
motor and SCIM is significantly different. The paired 
t‑test (normally distributed data) was used to analyze 
the difference between basal and follow‑up values. 
For all tests p<0.05 was considered significant. Statis‑
354 J.L. Quintanar et al. Acta Neurobiol Exp 2018, 78: 352–357
tical analysis was performed using GraphPad Prism 
7.0 for Windows (GraphPad Software, Inc., La Jolla, 
CA, USA). 
RESULTS 
During treatment, none of the patients presented 
complications related to LA treatment and no severe 
adverse events were observed. The main character‑
istics of patients are shown in Table I. The mean age 
of the patients was 33.4 years and with an average of 
31.5 months with SCI, which is considered a chronic pa‑
thology. The highest percentage of patients recorded 
was men and by vehicular accidents (both 85%). The 
most frequent lesions were at the cervical level (50%) 
followed by the thoracic (42.8%) and the least frequent 
were the lumbar (7.1%). Results of ASIA sensory, ASIA 
motor and SCIM scores before and after of 6 months of 
treatment are described in Table II. In the sensory anal‑
ysis of ASIA, 71% of patients reported an increase in the 
number of dermatomes (at least in one) that responded 
to the sensory stimulus after the treatment. While in 
motor ASIA, percentage of patients who increased the 
degree of mobility and/or strength in at least one mus‑
cle group of some limb was 57%. Further, SCIM scores 
revealed that 92% of the patients improved their level 
of independence after the treatment. Thus, statistical 
analysis showed a significant improvement in results of 
ASIA sensory score (87.2 ± 11 vs. 96.7 ± 10.7), ASIA motor 
score (35.9 ± 5.3 vs. 39.4 ± 4.9), and SCIM score (37.5 ± 
4.9 vs. 41.8 ± 5.0) comparing the initial evaluation and 
the end (6 months) of LA administration (Fig. 1). Ana‑
lyzing the recovery percentage of patients with respect 
to the ASIA maximum score, it was found that the sen‑
sory recovery was 4.3% (considering a score of 224 as 
100%). The motor recovery was 3.5% and the level of 
independence 6.3% (considering a maximum score of 
100 as 100% for both scores).
In addition to the recovery shown with the ASIA 
scores, five patients (35%) reported an increase in 
the frequency of bowel movements related to a great‑
er number of evacuations or a lower use of laxative 
substances. Also, a patient with a C8 lesion reported 
a greater sensitivity to changes in temperature (hot 
and cold) and a lower muscular effort to cough. 
DISCUSSION
The effect of the neurotrophin family; nerve 
growth factor, brain‑derived neurotrophic factor, neu‑
rotrophin‑3, and neurotrophin‑4/5, on neuroregener‑
ation in axons of injured spinal cord is well established 
(Kadoya et al. 2009). Likewise, it has been reported 
that the treatment with acidic fibroblast growth factor 
Table I. Clinical characteristics of subjects in the study.
Subject Gender Age (years)
Mechanism  
of injury Level of injury ASIA score
Injury time
(months)
1 M 64 Hernia L2 B 44
2 F 61 Vehicular T9 B 15
3 M 33 Vehicular C7 B 43
4 M 23 Vehicular C5 A 25
5 M 21 Vehicular T8 A 43
6 M 39 Vehicular C6 A 19
7 M 40 Vehicular C5 A 28
8 M 18 Vehicular T9 A 28
9 M 25 Vehicular C4 A 59
10 M 26 Fall C6 A 21
11 M 29 Vehicular T8 A 22
12 F 29 Vehicular C8 A 59
13 M 34 Vehicular T3 A 6
14 M 26 Vehicular T7 B 30
ASIA – American Spinal Injury Association. M – male, F – female.
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(aFGF) induced significant improvements in ASIA mo‑
tor and sensory scale scores and functional indepen‑
dence measures at 24 months after procedure (surgery 
is required for the administration of aFGF) (Wu et al. 
2008). Other clinical trials that use thyrotropin‑releas‑
ing hormone (TRH) with neurotrophic properties, re‑
port that an intravenous administration dose of TRH 
12 hours after SCI improved significantly the sensor 
and motor functions evaluated 4 months after the 
treatment (Pitts et al. 1995). 
In the present work, we report that the use of LA 
to enhance recovery of the human central nervous 
system is a novel and friendly method that provides 
a non‑invasive pharmacological treatment to patients 
with chronic SCI. With LA treatment, the degree of re‑
covery is partial; however, for the daily life of patients 
it is very significant. Of the fourteen patients included 
in this study, ten showed improvements in their senso‑
ry record (71%); eight in the motor function (57%) and 
thirteen in their SCIM score (92%). 
To explain these results, different mechanisms may 
be suggested by which LA may improve neurological 
functions. It is possible that the effects obtained by LA 
administration are due to the activation of receptors 
for GnRH present in the spinal cord. Previously, the 
presence of GnRH receptors in spinal cord neurons in 
animal models such as sheep (Dolan et al. 2003) and rat 
(Quintanar et al. 2007) has been described, and these 
receptors respond to stimulation with GnRH (Quin‑
tanar et al. 2016a). Once the receptors are activated, 
biochemical, morphological and functional changes 
could be generated in the injured nervous tissue.
Table II. Results of clinical evaluation in the initial and sixth month after LA treatment.
Patient
Sensorial ASIA Motor ASIA SCIM
ObservationsTime in months
Initial 6th % Recovery Initial 6
th % 
Recovery Initial 6
th % 
Recovery
1 176 192 7.1 64 70 6 71 76 5
2 108 116 3.6 50 50 0 35 39 4
3 93 104 4.9 50 54 4 28 35 7 ↑ Bowel management
4 40 40 0 1 1 0 0 0 0 Improve cought
5 116 115 ‑ 0.4 50 52 2 52 55 3
6 64 76 5.4 25 30 5 30 50 20 ↑ Bowel management
7 32 49 7.6 9 16 7 11 16 5 ↑ Bowel management
8 125 128 1.3 50 50 0 33 47 14
9 61 80 8.5 10 24 14 37 41 4
10 49 74 11.2 23 26 3 27 33 6 ↑ Bowel management
11 120 118 ‑ 0.9 50 50 0 54 58 4
12 40 45 2.2 21 29 8 28 32 4 Cold‑hot sensitivity,  improve cought
13 82 101 8.5 50 50 0 34 43 9 ↑ Bowel management
14 116 116 0 50 50 0 58 61 3
ASIA – American Spinal Injury Associ ation; SCIM – spinal cord independence measure. ↑ improvement.
Fig. 1. ASIA scores (sensory and motor) and SCIM score analysis of SCI 
patients with LA treatment every month for 6 months. Data represent 
the average ± SEM. The Wilcoxon signed rank test for independent 
samples was used. ASIA – American Spinal Injury Associ ation; SCIM – 
spinal cord independence measure. *P< 0.007; **P< 0.001. A paired 
Student t‑test was used to analyses the difference between basal and 
follow‑up values.
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In relation to biochemical changes, it has been de‑
scribed that GnRH, or its analogue LA, induces an in‑
crease in the expression of neuronal regeneration 
marker proteins such as 68 and 200 kDa neurofilaments 
and spinophilin in spinal cord neurons of rat in vivo 
(Calderón‑Vallejo and Quintanar 2012) and in vitro (Quin‑
tanar et al. 2016a). Likewise, LA induces an increase in 
myelin basic protein expression, a principal constitutive 
protein of myelin in oligodendrocytes of spinal cord in 
a model of multiple sclerosis (Guzmán‑Soto et al. 2012). 
In the morphological study of spinal cord, both 
GnRH and LA treatment increased the number and 
caliber of nerve axons, and the white matter was well 
preserved in SCI rats (Calderón‑Vallejo et al. 2015, 
Díaz‑Galindo et al. 2015). In SCI, the plasticity of ax‑
ons can be gained through processes of regeneration, 
where new axonal growth arises at the injury site from 
the cut end of an axon. Another possibility is axonal 
growth emerging from a spared axon adjacent to lesion 
site, or from a transected axon some distance from the 
site of transection (Hollis and Tuszynski 2011). 
In relation to the functional effects of GnRH and 
LA, locomotion activity was evaluated in rats with SCI. 
The results showed a partial but significantly improve‑
ment in locomotor activity and gait related to stride 
length and stride speed (Calderón‑Vallejo et al. 2015, 
Calderón‑Vallejo and Quintanar 2012, Díaz‑Galindo et al. 
2015). Quintanar et al. (2016b) reported a case of a male 
patient with chronic incomplete spinal cord injury (ASIA 
C) at level T‑9 treated with LA during 12 months. After 
the treatment, this patient increased the level of sen‑
sitivity in two dermatomes, as well as the mobility and 
strength in all the muscle groups of the lower extremi‑
ty by approximately 30%. The percentage of recovery in 
the group of patients described in this study was low‑
er than in the case reported previously. This difference 
may be due mainly to the magnitude of the lesion, since 
the patients included in this study have a higher degree 
of injury (ASIA A or B). It is possible that functional re‑
covery due to LA treatment may be greater if the amount 
of spinal cord tissue preserved after the injury is greater. 
It would be important to carry out a subsequent study 
focused on identifying the extent of recovery with the 
treatment of LA depending on the degree of injury.
On the other hand, it has been reported that the 
use of LA offers an effective therapeutic modality for 
patients with moderate to severe functional bowel 
disease (Mathias et al. 1998, Wilson et al. 2007). This 
is in agreement with our results, since we observed an 
improvement in patients with SCI in 5 of the 14 cases. 
It has been previously shown that GnRH receptors are 
present in the digestive tract in other mammals (Huang 
et al. 2001) and it is possible that LA could activate 
these receptors and thus, improve intestinal motility.
This study is useful, because it includes chronic pa‑
tients with SCI. Considering that all patients present 
a severe and chronic injury, the percentages of recovery 
obtained in this trial are significant since they directly 
impact on their daily life. Currently, few clinic treat‑
ment options exist for cases where the injury occurred 
several years ago; for example, trials with stem cells 
transplantation and removal of the scar (Young 2014). 
In addition to the effects on the nervous system, it 
has been reported that GnRH and LA have a direct ac‑
tion on the modulation of the function of the immune 
system. Specifically, it has been described that GnRH 
and LA treatments significantly reduce the expression 
of proinflammatory cytokines (Guzmán‑Soto et al. 
2016, Quintanar and Guzmán‑Soto 2013). Also, in rats 
with acute spinal cord injury, it was found that there 
was a decrease in activated microglia in the spinal cord 
of animals that received treatment with LA (Díaz‑Galin‑
do et al. 2015). Considering all previous results, we pro‑
pose that this treatment protocol could also be used for 
patients with acute injury; however, this option is for 
further research. Also, other complementary ways of 
evaluating the recovery effects of treatment with LA 
could be included; such as nuclear magnetic resonance, 
tomography and evoked potentials before and after of 
LA administration.
In conclusion, treatment with LA induces improve‑
ments in sensitivity, motor activity and independence in 
patients with chronic SCI. The main advantage of this 
protocol is that it is a non‑invasive method of easy and 
safe application, with few well described side effects and 
the drug already exists in commercial presentation.
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